These developments highlight the potential benefits for patients with bone metastases from ALK-positive NSCLC and other malignancies who may benefit from combining innovative bisphosphonate nanoformulations with next-generation ALK inhibitors. Here, ALK is linked to non-small cell lung carcinoma.